Trends of the Global Burden of Disease Attributable to Cannabis Use Disorder in 204 Countries and Territories, 1990–2019: Results from the Disease Burden Study 2019

[1]  Majid Alabdulla,et al.  Evolution of policy for the treatment of substance use disorders in Qatar , 2022, Substance Abuse Treatment, Prevention, and Policy.

[2]  F. Owiti,et al.  The prevalence and pattern of cannabis use among patients attending a methadone treatment clinic in Nairobi, Kenya , 2021, Substance Abuse Treatment, Prevention, and Policy.

[3]  J. Rehm,et al.  Public health monitoring of cannabis use in Europe: prevalence of use, cannabis potency, and treatment rates , 2021, The Lancet Regional Health - Europe.

[4]  Cannabis use and cannabis use disorder , 2021, Nature Reviews Disease Primers.

[5]  W. Hall,et al.  Cannabis use and cannabis use disorder , 2021, Nature Reviews Disease Primers.

[6]  S. Ndanyi.  Cannabis in Kenya , 2021, Journal for Contemporary History.

[7]  Socioeconomic characteristics and drug use disorders , 2020, World Drug Report.

[8]  Eun Sug Park,et al.  Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019 , 2020, Lancet.

[9]  Z. Dai,et al.  Trends of the incidence of drug use disorders from 1990 to 2017: an analysis based on the Global Burden of Disease 2017 data , 2020, Epidemiology and Psychiatric Sciences.

[10]  W. Hall,et al.  Assessing the public health impacts of legalizing recreational cannabis use: the US experience , 2020, World psychiatry : official journal of the World Psychiatric Association.

[11]  N. Dhingra,et al.  An Overview: Prevalence of Cannabis Abuse in India , 2020 .

[12]  Jun Lyu,et al.  Changes in the global burden of depression from 1990 to 2017: Findings from the Global Burden of Disease study. , 2020, Journal of psychiatric research.

[13]  J. Caulkins,et al.  Public health implications of legalising the production and sale of cannabis for medicinal and recreational use , 2019, The Lancet.

[14]  V. Zvonarev,et al.  The Public Health Concerns of Marijuana Legalization: An Overview of Current Trends , 2019, Cureus.

[15]  J. Rehm,et al.  Mortality from Alcoholic Cardiomyopathy: Exploring the Gap between Estimated and Civil Registry Data , 2019, Journal of clinical medicine.

[16]  N. Mayo,et al.  Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood: A Systematic Review and Meta-analysis , 2019, JAMA psychiatry.

[17]  O. Metadilogkul,et al.  Social, religious, recreational and medicinal usage of cannabis in India and Thailand , 2019 .

[18]  Jacek Kopec,et al.  The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The lancet. Psychiatry.

[19]  I. Grant,et al.  Medical cannabis legalization and opioid prescriptions: evidence on US Medicaid enrollees during 1993–2014 , 2018, Addiction.

[20]  J. Hockenberry,et al.  Association of Medical and Adult-Use Marijuana Laws With Opioid Prescribing for Medicaid Enrollees , 2018, JAMA internal medicine.

[21]  A. Abraham,et al.  Association Between US State Medical Cannabis Laws and Opioid Prescribing in the Medicare Part D Population , 2018, JAMA internal medicine.

[22]  N. Volkow,et al.  Cannabis Addiction and the Brain: a Review , 2018, Journal of Neuroimmune Pharmacology.

[23]  Z. Cooper,et al.  Sex-Dependent Effects of Cannabis and Cannabinoids: A Translational Perspective , 2018, Neuropsychopharmacology.

[24]  X. Wan,et al.  Is the Mortality Trend of Ischemic Heart Disease by the GBD2013 Study in China Real? , 2017, Biomedical and Environmental Sciences.

[25]  T. Vos,et al.  Guidelines for Accurate and Transparent Health Estimates Reporting: the GATHER statement , 2016, PLoS medicine.

[26]  Viktoriya Magid,et al.  Cannabis Use Disorder in Adolescence. , 2016, Child and adolescent psychiatric clinics of North America.

[27]  C. Cuttler,et al.  Sex Differences in Cannabis Use and Effects: A Cross-Sectional Survey of Cannabis Users , 2016, Cannabis and cannabinoid research.

[28]  K. Kampman,et al.  Adverse Effects of Marijuana Use , 2016, The Linacre quarterly.

[29]  C. Cunningham,et al.  Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. , 2014, JAMA internal medicine.

[30]  Françoise de Bel-Air.  Demography, migration, and labour market in Qatar , 2014 .

[31]  Richie Poulton,et al.  Persistent cannabis users show neuropsychological decline from childhood to midlife , 2012, Proceedings of the National Academy of Sciences.

[32]  J Michael Bostwick,et al.  Blurred boundaries: the therapeutics and politics of medical marijuana. , 2012, Mayo Clinic proceedings.

[33]  Wayne Hall,et al.  Extent of illicit drug use and dependence, and their contribution to the global burden of disease , 2012, The Lancet.

[34]  T. Rubino,et al.  Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models , 2010, British journal of pharmacology.

[35]  D. Segal.  Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) , 2010 .

[36]  S. Tapert,et al.  The influence of marijuana use on neurocognitive functioning in adolescents. , 2008, Current drug abuse reviews.

[37]  M. Cohen-Zion,et al.  Neuropsychological functioning in adolescent marijuana users: Subtle deficits detectable after a month of abstinence , 2007, Journal of the International Neuropsychological Society.

[38]  A. Odejide.  Status of Drug Use/Abuse in Africa: A Review , 2006, International Journal of Mental Health and Addiction.

[39]  All-India Institute of Medical Sciences , 1961 .